SABCS 2022

Part 3: Testing for TROP-2 not needed / no prognostic factor found

Part 2: Treamtent options in high-risk breast cancer

Part 1: Encouraging data that supports treatment decisions, but better focus on racial and social disparities is needed

Practice Changing ADC data confirmed

New insights: Are CTCs predictive or not?

SERDs - who benefits? ESR1 testing required?

New treatment perspectives in luminal breast cancer

monarchE confirms increasing benefit. What are the real life implications?

ADC: Do we need a target? Do we need a predicitve marker?

New evidence regarding the chance of pregnancies in EBC

RIGHT choice against Chemotherapy for aggressive disesase

Abemaciclib as standard of in high-risk HR+ HER2- primary BC

Adjuvant TH confirms excellent logn-term follow-up

Chemo without benefit in node-negative disease

Time to reconsider Ki-67 threshold?!

First trial about pregnancy in premenopausal early BC patients during their endocrinee adjuvant therapy

Platin-based neoadjuvant therapy in early TNBC: impact in pCR and prognosis in younger patients

Benefit of extended adjuvant treatment with endocrine therapy based on genomic profiling with Mammaprint

Interruption of endocrine therapy in case of desire to have children

T-DXd as (neo)adjuvant treatment HR+/HER2- patients

monarchE confirms data once more.

POSITIVE-Trial shwos that temporal therapy interruption is safe and allows pregnancy

Good news for young patients

El primer estudio sobre la gestación en pacientes con cáncer de mama precoz premenopaúsicas durante el tratamiento endocrino adyuvante

Beneficio del tratamiento hormonal extendido según resultados de expresión génica con el test Mammaprint

Neoadyuvancia con carboplatino en cáncer de mama precoz y fenotipo triple negativo: impacto en RCp y pronóstico en mujeres jóvenes

T-DXd as (neo)adjuvant treatment HR+/HER2- patients

POSITIVE-Trial dimostra che l'interruzione temporanea della terapia endocrina adiuvante è sicura e consente la gravidanza

Highlights on oral SERDS in HR+ mBC

A shift from chemotherapy to CDK4/6

Targeted approach for endocrine responsive visceral disease

SERENA-2 showed better PFS by camizestrant compared with fulvestrand

Progress in research and clinic

SERENA-2 ha mostrato una migliore PFS grazie a camizestrant rispetto a fulvestrant

Il miglior approccio per la malattia endocrino-responsiva con malattia viscerale

Highlights on oral SERDS in HR+ mBC

HR+/HER2-: Who still needs chemotherapy?

Endocrine combination despite visceral crisis

Treatment alternatives to chemotherapy for visceral crisis

Continuing Palbociclib beyond progression does not improve PFS

De-escalation in triple positive MammaCa

Ribociclib + endocrine in high risk HR+/HER2- MBC superior to chemo

RIB + ET appears to be the better option than chemotherapy in the 1stLine even in patients with aggressive HR+/HER2- BC

CDK4/6 inhibitors - a preferred option also for the highest risk patients

Inhibitory CDK4/6 opcją z wyboru również u chorych najwyższego ryzyka

T-DXd new standard after pretreatment with trastuzumab and a taxane in HER2+ mBC

T-DXd with so far unkown efficacy

T-DXd as therapy of choice even after T-DM1 in HER2+ mBC

Important OS update for T-DXd

Optimal side effect management required

Positive data for ER+ and HER2+ breast cancer

T-Dxd keeps us excited

TDXd is the prefered option for pts previously treated with T-DM1

Clinically relevant and statistically significant benefit in OS and PFS with T-DXd

Chemotherapy-free (neo)adjuvant treatment seems feasible for HR+/HER2- patients with T-DXd

Robust benefit of T-Dxd confirmed with new data

T-Dxd - ready for prime time in the 2nd line

Great data - as usual with T-Dxd

TDXd es la primera opción para pacientes tratados previamente con T-DM1

Positive data for ER+ and HER2+ breast cancer

T-DXd – skuteczność, jakiej dotąd nie znaliśmy

Importante actualisation des données de survie globale pour le T-DXd

Beneficio clínicamente y estadísticamente significativo en OS y PFS con T-DXd

A new drug in the endocrine landscape

Positive data for ER+ and HER2+ breast cancer

Oral SERDs are superior

oral SERDs on the rise?

Une nouvelle molécule dans le traitement hormonal du cancer du sein

Una nouva molecola nel trattamento ormonale del tumore al seno

Positive data for ER+ and HER2+ breast cancer

AKT inhibitor capivasertib in HR+ mBC

CTC count may help in therapy decisions

Olaparib as an alternative to carboplatin in aggressive HR+/HER2- mBC?

CTCs with metastatic breast cancer re-visited

Capivasertib - A drug for allcomers

ADC or other therapies after CDK4/6

Positive data for ER+ and HER2+ breast cancer

Promising new player in the second line setting in advanced luminal BC

Triple-positive MBC does not require chemotherapy.

Pregnancies after primary breast cancer

Her2-low discordance rate at 40%

Estradiol withdrawal affects the micromillieu in the brain

Obiecująca nowa opcja w drugiej linii zaawansowanego, luminalnego raka piersi

Capivasertib un nuovo standard per tutti?

Le compte des CTC peut orienter la décision thérapeutique

Positive data for ER+ and HER2+ breast cancer

TNBC - Practice changing data lead to new approvals - and more to come!

HER2+ - no new approval but long-term follow up data confirm established therapies

HR+ - Practice changing data - which therapy for which patients?

New Indications: ADCs & HER2-low

The Right Choices? CDK4/6i vs. Chemo, SERDs & ESR1?

Dealing with Brain mets / Update TNBC